Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.
Drucker
Daniel J
DJ
Department of Medicine, Samuel Lunenfeld Research Institute, University of Toronto, Toronto, Ontario, Canada. d.drucker@utoronto.ca
Sherman
Steven I
SI
Gorelick
Fred S
FS
Bergenstal
Richard M
RM
Sherwin
Robert S
RS
Buse
John B
JB
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology; D004334:Drug Administration Schedule; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000819:agonists; D006801:Humans; D007004:Hypoglycemic Agents / Q000145:classification / Q000627:therapeutic use*; D015994:Incidence; D054795:Incretins / Q000009:adverse effects / Q000627:therapeutic use*; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use; D015995:Prevalence; D018570:Risk Assessment; D016896:Treatment Outcome; D014688:Venoms / Q000008:administration & dosage / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D054795:Incretins; D010455:Peptides; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide